Mandate

Vinge advises Region Uppsala in connection with health impact bonds

December 14, 2023 Banking and Finance

Vinge has advised Region Uppsala in connection with its issuance of a so-called health impact bond in the amount of SEK 80 million and with a tenor of five years. The health impact bond is the second of its kind in the world and comes after Region Stockholm’s bond which was linked to preventive measures against type 2 diabetes. Skandia was the sole investor and SEB acted as financial advisor and issuing agent.

The health impact bond is a bespoke product that finances preventive interventions to detect and offer potentially life-saving treatment to people with undiagnosed high blood pressure and other related risk factors. The preventive interventions are expected to prevent up to 650 materially adverse cardiovascular events and generate cost savings of approximately SEK 160 million over ten years.

A distinct and unique feature of the health impact bond is its yield model, which is outcome-based and involves risk sharing between the issuer and the investor. If the issuer’s initiatives achieve the expected results, the investor will receive a higher return on its investment, but if the issuer does not achieve the expected results, the return will be lower or even negative (i.e., the investor will get back less than their invested amount).

For more information (Swedish only), please refer to https://regionuppsala.se/politik-och-paverkan/pressrum/2023/december/satsar-stort-mot-hogt-blodtryck-genom-att-ge-ut-halsoobligation/.

The Vinge team consisted of Albert Wållgren, Lionardo Ojeda and Sofia Haggren.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026